Show
Sort by
-
- Journal Article
- A1
- open access
RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition
-
Targeted therapy of TERT-rearranged neuroblastoma with BET bromodomain inhibitor and proteasome inhibitor combination therapy
-
- Journal Article
- A1
- open access
The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness
-
Accelerating drug development for neuroblastoma : summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma
-
- Journal Article
- A1
- open access
Phase I dose‐escalation study of volasertib in pediatric patients with acute leukemia or advanced solid tumors
-
- Journal Article
- A1
- open access
Integrative analysis identifies lincRNAs up- and downstream of neuroblastoma driver genes
-
- Journal Article
- A1
- open access
The long noncoding RNA lncNB1 promotes tumorigenesis by interacting with ribosomal protein RPL35
-
LDHA in neuroblastoma is associated with poor outcome and its depletion decreases neuroblastoma growth independent of aerobic glycolysis
-
Circulating microRNA biomarkers for metastatic neuroblastoma
-
The RRM2-PHF6 complex protects neuroblastoma cells from DNA damage accumulation to install a replication stress resistance phenotype